Indication Global
Market Size
Pre
Clinical
Phase
Ib
Phase
IIb
Support for EU Conditional
Marketing Approval
Submission
Post EU
Marketing
US Phase 3
Organ failure associated with Sepsis $33B   Completed Phase II Initiated
Q1 2021
Completion of Phase
II Q3 2023
 
               
Advanced-stage soild tumors with
peritoneal metastases in
combination with chemotherapy
$4B   Phase lb
Q2 2022
     
               
Advanced-stage soild tumors with
peritoneal metastases stand-alone,
+ in combination with anti-PD1
$4B   Phase I/II
Q3 2022
     
               

Recent Publications